PET Scan Checks HER2 Levels to Predict Response in Bladder Cancer
Tests a HER2 PET scan in adults with bladder cancer treated with ADC.
Plain-language title generated from the registry record
Registry title: HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06548529, who can take part
Where in China
- uEXPLORER total-body PET/CT scanner (United Imaging, China)Beijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University Cancer Hospital & Institute
- Trial code
- NCT06548529
- Record updated
- 23 August 2024
- Original description
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADCRead full original descriptionShow less
Al18F-HER2-BCH PET/CT to Predict Response in Bladder Cancer Patients Treated With HER2 ADC
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
Inclusion: Aged # 18 years old; ECOG 0 or 1; Is unresectable or metastatic; Patients with HER2 positive or suspicious positive tumors; was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane; Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; Receives anti-HER2 ADC treatment; Life expectancy > 3 months.
Exclusion: Suffering from claustrophobia or other mental disorders; Significant hepatic or renal dysfunction; Is pregnant or ready to pregnant; Cannot keep their states for half an hour; Refused to join the clinical research; Any other situation that researchers considered it unsuitable to participate in the trial.